KR101781954B1 - Method for producing mushroom mixed beverage using Lentinula edodes, Phellinus linteus and medical herb extract and mushroom mixed beverage produced by the same method - Google Patents
Method for producing mushroom mixed beverage using Lentinula edodes, Phellinus linteus and medical herb extract and mushroom mixed beverage produced by the same method Download PDFInfo
- Publication number
- KR101781954B1 KR101781954B1 KR1020150091759A KR20150091759A KR101781954B1 KR 101781954 B1 KR101781954 B1 KR 101781954B1 KR 1020150091759 A KR1020150091759 A KR 1020150091759A KR 20150091759 A KR20150091759 A KR 20150091759A KR 101781954 B1 KR101781954 B1 KR 101781954B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- mushroom
- minutes
- malt
- mushroom mixed
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 129
- 235000001674 Agaricus brunnescens Nutrition 0.000 title claims abstract description 81
- 235000013361 beverage Nutrition 0.000 title abstract description 35
- 238000000034 method Methods 0.000 title abstract description 23
- 238000004519 manufacturing process Methods 0.000 title description 26
- 240000000599 Lentinula edodes Species 0.000 title 1
- 235000001715 Lentinula edodes Nutrition 0.000 title 1
- 241000001727 Tropicoporus linteus Species 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 27
- 238000002156 mixing Methods 0.000 claims abstract description 24
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims abstract description 22
- 235000017491 Bambusa tulda Nutrition 0.000 claims abstract description 22
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims abstract description 22
- 239000011425 bamboo Substances 0.000 claims abstract description 22
- 235000006533 astragalus Nutrition 0.000 claims abstract description 21
- 239000000203 mixture Substances 0.000 claims abstract description 21
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229940069445 licorice extract Drugs 0.000 claims abstract description 16
- 241001105098 Angelica keiskei Species 0.000 claims abstract description 11
- 238000010438 heat treatment Methods 0.000 claims abstract description 8
- 244000082204 Phyllostachys viridis Species 0.000 claims abstract 3
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 13
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 13
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 13
- 229940010454 licorice Drugs 0.000 claims description 13
- 235000019198 oils Nutrition 0.000 claims description 6
- 240000001810 Angelica gigas Species 0.000 claims description 3
- 235000018865 Angelica gigas Nutrition 0.000 claims description 3
- 240000004922 Vigna radiata Species 0.000 claims description 2
- 235000010721 Vigna radiata var radiata Nutrition 0.000 claims description 2
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 claims description 2
- 241000202807 Glycyrrhiza Species 0.000 claims 2
- 241000209020 Cornus Species 0.000 claims 1
- 241000234280 Liliaceae Species 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 241001632410 Eleutherococcus senticosus Species 0.000 abstract description 9
- 238000000605 extraction Methods 0.000 abstract description 8
- 235000002262 Lycopersicon Nutrition 0.000 abstract description 3
- 241000227653 Lycopersicon Species 0.000 abstract description 3
- 238000004458 analytical method Methods 0.000 description 26
- 230000003712 anti-aging effect Effects 0.000 description 26
- 229940024606 amino acid Drugs 0.000 description 25
- 235000001014 amino acid Nutrition 0.000 description 25
- 150000001413 amino acids Chemical class 0.000 description 25
- 239000000047 product Substances 0.000 description 21
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 20
- 241001330002 Bambuseae Species 0.000 description 19
- 239000002994 raw material Substances 0.000 description 16
- 230000036541 health Effects 0.000 description 15
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 14
- 235000000346 sugar Nutrition 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- 230000003078 antioxidant effect Effects 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 240000004670 Glycyrrhiza echinata Species 0.000 description 10
- 230000032683 aging Effects 0.000 description 10
- 235000005687 corn oil Nutrition 0.000 description 10
- 239000002285 corn oil Substances 0.000 description 10
- 229960005489 paracetamol Drugs 0.000 description 10
- 238000010586 diagram Methods 0.000 description 9
- 235000001287 Guettarda speciosa Nutrition 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 239000003963 antioxidant agent Substances 0.000 description 8
- 235000006708 antioxidants Nutrition 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 235000019640 taste Nutrition 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 210000003494 hepatocyte Anatomy 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000000470 constituent Substances 0.000 description 6
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000001953 sensory effect Effects 0.000 description 6
- 229920001503 Glucan Polymers 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000007760 free radical scavenging Effects 0.000 description 5
- 235000013376 functional food Nutrition 0.000 description 5
- 241000411851 herbal medicine Species 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 4
- 244000061520 Angelica archangelica Species 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 229920002498 Beta-glucan Polymers 0.000 description 4
- 102000029816 Collagenase Human genes 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 240000002045 Guettarda speciosa Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 230000002292 Radical scavenging effect Effects 0.000 description 4
- 229960002424 collagenase Drugs 0.000 description 4
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000007974 sodium acetate buffer Substances 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108060005980 Collagenase Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229960003767 alanine Drugs 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000012676 herbal extract Substances 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 229960005190 phenylalanine Drugs 0.000 description 3
- 235000008729 phenylalanine Nutrition 0.000 description 3
- 229960001153 serine Drugs 0.000 description 3
- 238000012453 sprague-dawley rat model Methods 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- -1 Co-Q Chemical compound 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010013911 Dysgeusia Diseases 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101000851058 Homo sapiens Neutrophil elastase Proteins 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 240000000249 Morus alba Species 0.000 description 2
- 235000008708 Morus alba Nutrition 0.000 description 2
- 240000005125 Myrtus communis Species 0.000 description 2
- 235000013418 Myrtus communis Nutrition 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- 229940110767 coenzyme Q10 Drugs 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000020510 functional beverage Nutrition 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 102000052502 human ELANE Human genes 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000007449 liver function test Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- PJVXUVWGSCCGHT-ZPYZYFCMSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO PJVXUVWGSCCGHT-ZPYZYFCMSA-N 0.000 description 1
- ZCUQOPGIJRGJDA-UHFFFAOYSA-N 1-naphthalen-1-ylethane-1,2-diamine Chemical compound C1=CC=C2C(C(N)CN)=CC=CC2=C1 ZCUQOPGIJRGJDA-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 229920000310 Alpha glucan Polymers 0.000 description 1
- 241000092897 Angelica japonica Species 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 240000001548 Camellia japonica Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 241001061533 Cyathus stercoreus Species 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 208000018035 Dental disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241001313710 Dictyophora indusiata Species 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000005206 Hibiscus Nutrition 0.000 description 1
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 description 1
- 244000284380 Hibiscus rosa sinensis Species 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 244000179970 Monarda didyma Species 0.000 description 1
- 235000010672 Monarda didyma Nutrition 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 208000014151 Stomatognathic disease Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 230000007131 anti Alzheimer effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001399 anti-metabolic effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229940069780 barley extract Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 229930186243 clitocybin Natural products 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 235000018597 common camellia Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229930184327 cyathusal Natural products 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000002554 disease preventive effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000002431 foraging effect Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 108010046301 glucose peroxidase Proteins 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000037209 prostate health Effects 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000005245 right atrium Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229930192002 syriacusin Natural products 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
Abstract
The present invention relates to a method for preparing a mushroom mixture, comprising: (a) preparing a mushroom mixed extract by mixing water and a conditional extract, (b) preparing water extracts of Angelica keiskei koidz., Acanthopanax senticosus, Acanthopanax senticosus, Acanthopanax senticosus, Lycopersicum blooms, and Malt extracts, respectively, followed by extraction; And (c) mixing the mushroom mixed extract prepared in the step (a) and the Angelica keiskei bark extract prepared in the step (b), Sanswu oil extract, Hwanggi extract, bamboo leaf extract, licorice extract and malt extract, followed by heating And a mushroom mixed beverage produced by the method.
Description
The present invention relates to a mushroom mixture comprising a mushroom mixed extract obtained by mixing a mushroom mixed extract with a mushroom mixture, a mushroom extract, a mushroom extract, a mushroom extract, a bamboo mushroom extract, a licorice extract and a malt extract, And a mushroom mixed drink produced by the method.
As the aging of the population is rapidly progressing in the world and the income level is rising, the anti-aging industry is growing fast and the national social importance is increasing. The anti-aging industry consists of anti-aging products, anti-aging medical devices, anti-aging products, anti-aging products and anti-aging services such as health care services and appearance management services. , Which has grown at an annual average rate of 11%.
According to BCC Research, the global market size of anti-aging industries is expected to grow at a CAGR of 11.1% from USD132.5bn in 2006 to USD274.5bn in 2013. As a result of this rapid growth, the aging population is aging and the purchasing power of the elderly is expanding, and there is a high priced anti-aging product and service market for healthy old age. In addition, the demand for anti-aging industry is increasing in the young age as the economic level is improved and interest in health and appearance is increased.
The emergence of anti-aging industry has the effect of reducing social medical expenses by preventing disease through proactive health care and prevention of aging from the viewpoint of economic and social aspect, and on the other hand, This is important because it can be a growth engine that can drive economic growth based on demand.
A clear and common definition of the anti-aging and anti-aging industries has not yet been established, but from a comprehensive standpoint, the anti-aging industry is the product of prevention and management of aging mechanisms and all products that prevent, manage and cure physical diseases Service. ≪ / RTI > The detailed areas include anti-aging products, anti-aging products, anti-aging cosmetics, and anti-aging medical device industry. As for the aging industry, The market for aging drugs is expected to reach $ 899.7 billion in 2015, an annual average growth rate of 11.9%, which was the market size of $ 289.4 billion in 2005.
The anti-aging industry market in Korea is expected to show rapid growth similar to the growth of the global market. The anti-aging market, which was about 11 trillion won in 2010, will grow at an average annual rate of 9.5% It is expected. Looking at the market forecasts for anti-aging products, anti-aging drugs are expected to grow at a CAGR of 12.4% from W2.64 trillion in 2005 to 6.668 trillion won in 2015, .
In the anti-aging product market, aging prevention and health maintenance drugs account for more than 80% of the total market. The global market has increased from 115 million won in 2006 to 138 billion won in 2008, and it is expected to increase to 252 billion won in 2015 . By country, the US accounted for 34 ~ 36%, Europe 29 ~ 30%, and Japan 9 ~ 10%. Health supplements account for around 5% of the total anti-aging product market. It increased from $ 6.8 billion in 2006 to $ 7.6 billion in 2008 and is estimated to increase to $ 11.3 billion by 2015. By country and region, the US is 34 ~ 35%, Europe 31 ~ 32%, Japan 9 ~ 10%.
In Korea, the Health Functional Food Act was enacted in 2002, and a full-fledged market began to be formed in 2004. In the early days, red ginseng products and ginseng products using ginseng were mainly produced, and glucosamine, which is effective in preventing joint diseases, had a high sales. In recent years, the product has been diversified as a product for the elderly has been consumed for various age groups. Functional mainstream was antioxidant, fatigue recovery, blood circulation improvement, and cholesterol improvement, but it was classified into prostate health and eye health.
Domestic anti-aging active substance development project is the first stage, and most of the aging researches centered on the Korean Aging Society focus on inhibition of antioxidative activity as fundamental researches such as aging mechanism, and the following compounds are being researched and developed.
Matenoside compounds
- It contains diverse low-molecular physiologically active materials such as rutin, tannin, chlorogenic acid, caffeine, theobromine, and uricol, and various functions such as antioxidation, anti-cancer and Alzheimer improvement have been reported recently.
Syriacusins Compound
- Syriacus hibiscus extract inhibited HNE (human neutrophil elastase) activity.
Clitocybin Compound
- The clitosavibin compound has similar or superior antioxidative activity to catechin, a potent antioxidant. The clitosavibin compound has a specific structure as a pure natural product isolated from a native culture of mycelial mushroom mycelium and exhibits excellent antioxidative activity and is expected to be useful as a functional food material using this activity in the future.
Cyathusals Compound
- It was confirmed that Cyathus stercoreus strain, a kind of domestic native mushroom, produces strong antioxidant activity.
The following is a list of materials that are being researched and developed by companies.
1) Antioxidant products
Contains vitamin A, C, E, melatonin, estrogen, EGCG, Co-Q, lipoic acid,
Ex) Jeunesse (Italian Parmalat company, coenzyme Q10), seed oil (Teutoburger Olmuhle, coenzyme Q10) and others
2) preventive foods for geriatric diseases
Prevent skin aging, improve memory, prevent Alzheimer, improve vision / hearing deterioration, improve dental disease, improve sexual dysfunction, prevent osteoporosis / arthritis
Ex) herbal cosmetics XIANGNI, PME88 melon sod et al.
3) Anti-metabolic disease preventive food
Barley, beans, dietary fiber, phenolic compounds, enzyme inhibitors, etc.
Ex) Angiotensin (vegetable protein) (1993), Acoruka Medellabbilan Ollender of Sweden, 'An enteric preparation for obesity treatment', CJ Patdown, Dietp et al.
4) Cardiovascular disease prevention food
Prevention of hypertension at home and abroad, improvement of blood circulation, improvement of blood neutrality
Ex) Lyme,
Antioxidant-related products for anti-aging as described above have been marketed, but most of the products are mainly pharmaceuticals, health functional foods, and cosmetic products. These products have a strong feeling of medicine, and they have a feeling of discomfort about the part of the elderly that they consume as patients.
Food industry In the silver industry, various health foods are representative. When you become an elderly person, your immune system weakens, digestive function decreases, and you are exposed to various diseases. However, there are many cases where health foods that are eaten for health are rather harmful to health. Apart from the damage caused by the ill-mannered elderly people whose judgment is overpowered, the damage caused by exaggerated advertising of similar health foods without proven efficacy is not negligible. Even if the health functional food proved to be effective, there is a side effect caused by abuse that I follow because I like others. It is important to remember that health functional foods are not medicines and their efficacy varies depending on their health status and nutritional intake level. In the case of elderly people, ingestion of health food due to reduced digestive power, side effects such as digestive disorders, diarrhea and abdominal pain may also occur. Therefore, the development of a food-type product that is a mixture of medicinal materials and edible materials, which are registered as safe food ingredients, will help the healthy life of the elderly.
Korean Patent No. 1422611 discloses a method for manufacturing health beverages using mushroom, mulberry leaf, camellia seed, hornbug fruit, and gingko mushroom, and Korean Patent No. 1470949 discloses a method for producing beverages containing a mixture of mushroom extract and barley extract However, the method is different from the method of producing mushroom mixed beverage using the elevation, the situation and the herbal extract of the present invention.
SUMMARY OF THE INVENTION The present invention has been made in view of the above needs, and it is an object of the present invention to provide a method for preparing a natural product having rich antioxidant and immune function, amino acid rich condition, The present invention has been accomplished by preparing a mushroom mixed beverage having a wide range of functionality and containing a large amount of amino acids without increasing odor and optimizing the production conditions such as mixing ratio.
In order to solve the above problems, the present invention provides a method for preparing a mushroom mixture, comprising: (a) preparing a mushroom mixed extract by mixing water and a conditional extract, (b) preparing water extracts of Angelica keiskei koidz., Acanthopanax senticosus, Acanthopanax senticosus, Acanthopanax senticosus, Lycopersicum blooms, and Malt extracts, respectively, followed by extraction; And (c) mixing the mushroom mixed extract prepared in the step (a) and the Angelica keiskei bark extract prepared in step (b), Sanswort oil extract, Hwanggi extract, bamboo leaf extract, licorice extract and malt extract, followed by heating The present invention also provides a method for producing a mushroom mixed beverage.
The present invention also provides a mushroom mixed drink produced by the above method.
The present invention extracts and blends the herbal medicine having the condition and the elevation, antioxidant and immunity functions under optimal conditions to make it rich in amino acid while taking advantage of the simple characteristics possessed by each material, and also has antioxidant, By developing functional beverages, consumers can further improve their health. In addition, the mushroom mixed beverage of the present invention is excellent in taste and easy to drink, and does not cause any problem even if it is used in a large amount for a long period of time without adding any food additives, thereby providing a specialized health drink for the elderly.
FIG. 1 is a diagram illustrating a production process of the hot-water extract of the present invention.
2 is a diagram illustrating a process for producing an elevated hot-water extract of the present invention.
FIG. 3 is a diagram illustrating a manufacturing process of the hot water extract of Angelica gigas Nakai of the present invention.
FIG. 4 is a diagram illustrating a process for producing a hot water extract of corn oil according to the present invention.
FIG. 5 is a diagram illustrating a process for producing the water extract of the present invention.
FIG. 6 is a diagram illustrating a process for producing the licorice extract of the present invention.
FIG. 7 is a diagram illustrating a process for producing the bamboo leaf water extract of the present invention.
8 is a diagram illustrating a process for producing the malt hot-water extract of the present invention.
FIG. 9 is a diagram illustrating a manufacturing process of the mushroom mixed beverage of the present invention.
Figure 10 shows a photograph of the mushroom mixed drink of the present invention.
11 is a graph comparing the DPPH radical scavenging ability according to the concentration of mushroom extract, herbal medicine extract, and mushroom mixed drink (health mushroom tea) of the present invention.
12 is a graph comparing LDH, AST and ALT contents of acetaminophen and the mushroom extract, herb medicine extract and mushroom mixed beverage according to the present invention.
4: Acetaminophen + Angelica gigantosa extract treatment, 5: Acetaminophen + malt extract treatment, 6: Acetaminophen + saponin extract treatment, 7: Acetaminophen + 9: Acetaminophen + Lipid Extract Treatment, 10: Acetaminophen + Hwanggi Extract Treatment, 11: Acetaminophen + Mushroom Mixed Beverage Treatment
FIG. 13 is a graph comparing the amount of NO produced according to the treatment of each sample by inducing an inflammatory reaction by treating LPS with macrophages.
1: LPS treatment, 2: LPS treatment, 3: LPS + licorice extract treatment, 4: LPS + angelica extract treatment, 5: LPS + malt extract treatment, 6: LPS + , 8: LPS + bamboo extract treatment, 9: LPS + highland extract treatment, 10: LPS + Hwanggi extract treatment, 11: LPS + mushroom mixed beverage treatment
In order to achieve the object of the present invention,
(a) preparing a mushroom mixed extract by mixing water and a conditional extract and a surface extract prepared by extracting the mushroom mixed extract;
(b) preparing water extracts of Angelica keiskei koidz., Acanthopanax senticosus, Acanthopanax senticosus, Acanthopanax senticosus, Lycopersicum blooms, and Malt extracts, respectively, followed by extraction; And
(c) mixing the mushroom mixed extract prepared in step (a) and the Angelica keiskei kotsus extract prepared in step (b), corn oil extract, Hwanggi extract, bamboo leaf extract, licorice extract and malt extract, followed by heating And a method for producing a mushroom mixed beverage.
In the method for producing a mushroom mixed beverage of the present invention, the mixing of the step (a) may be performed by mixing the conditional extract and the mushroom extract in a volume ratio of 70 to 90: 110 to 130, more preferably, The topical extract may be mixed at a volume ratio of 70: 130, 80: 120 or 90: 110. Mixing the situation and elevation at the above ratio can be made into a beverage which is easy to drink because the taste and aroma of the elevation and the elevation are well mixed and the degree of preference is excellent.
In addition, in the method for producing mushroom mixed beverage of the present invention, the conditional extract of step (a) can be extracted preferably at 70 to 80 DEG C for 80 to 100 minutes, more preferably at 75 DEG C for 90 minutes The extract can be extracted preferably at 95 to 105 캜 for 40 to 60 minutes, more preferably at 100 캜 for 50 minutes. Extracting the condition and elevation under the above extraction conditions could extract the mushroom - specific odor without deteriorating the nutrients and flavor of the mushroom and extracting it with the extract suitable for high quality beverage with improved preference.
In addition, in the method for producing mushroom mixed beverage of the present invention, the Angelica giganta extract of step (b) can be extracted preferably at 85 to 95 캜 for 40 to 60 minutes, more preferably at 90 캜 for 50 minutes The extract may be preferably extracted at 95 to 105 ° C for 90 to 110 minutes, more preferably 100 ° C for 100 minutes, and the Hwanggi extract preferably has 95 to 105 Deg.] C for 110 to 130 minutes, more preferably 120 [deg.] C for 120 minutes, and the licorice extract can be extracted preferably at 95 to 105 [deg.] C for 30 to 50 minutes, , The bark extract can be extracted at 75 to 85 ° C for 50 to 70 minutes, more preferably at 80 ° C for 60 minutes, and the malt extract can be extracted from the malt The extract preferably contains 50 to 70 < RTI ID = 0.0 > It is to be extracted, and more preferably while it is possible to extract at 90 ℃ for 60 minutes. It is preferable to extract each herb medicine separately as described above because the extraction conditions for extracting the active ingredient to the maximum and improving the preference degree are different depending on the kinds of herb medicine, and it is preferable to extract the herb medicine as the above- And its pharmacological effect was excellent, and the bitter taste unique to herb medicine was reduced, and the taste was neat because it was not stiff but it could be made into an extract suitable for beverage production.
In the method for producing a mushroom mixed beverage according to the present invention, the mixing of step (c) is preferably carried out by mixing the mushroom mixture extract, Angelica keiskei koidz. Extract, corn oil extract, Hwanggi extract, bamboo leaf extract, licorice extract, The mixture can be mixed at a volume ratio of 80 to 120: 65 to 75: 75 to 85: 25 to 35: 8 to 12: 8 to 12, more preferably mixed with mushroom extract, Angelica gigantosa extract, Extract, licorice extract and malt extract can be mixed at a volume ratio of 300: 100: 70: 80: 30: 10: 10. The combination of the ingredients and the blending ratio to produce a beverage can produce a beverage having excellent taste because the taste and flavor of the mushroom and herbal medicine are well combined.
The method for producing the mushroom mixed drink of the present invention is more specifically
(a) The conditional extracts were prepared by adding water 18 to 22 times (w / v) to each of the condition and the oily lotion, and then extracted at 70 to 105 ° C for 40 to 100 minutes. To prepare a mushroom mixed extract;
(b) 18 ~ 22 times (w / v) water was added to each of Angelica japonica, Sansui oil, Hwanggi, licorice, bamboo leaf and malt and then extracted at 75 ~ 105 ℃ for 30 ~ 130 minutes. , Bamboo leaf extract, licorice extract and malt extract; And
(c) extracting the mushroom mixed extract prepared in the step (a) and the Angelica keiskei L. extract, myrtle extract, myrtle oil extract, bergamot extract, bamboo leaf extract, licorice extract and malt extract prepared in step (b) To 75: 75 to 85: 25 to 35: 8 to 12: 8 to 12, followed by heating at a temperature of 90 to 110 ° C for 15 to 25 minutes,
More specifically,
80 to 120, or 90: 100, respectively, of the conditional extract and the extract prepared by extracting the extracts at 75 to 100 ° C for 50 to 90 minutes after adding 20 times (w / v) 110 volume ratio to prepare a mushroom mixed extract;
(b) 20 times (w / v) water was added to each of Angelica gigas Nakai, Sansui oil, Hwanggi, Licorice, Bamboo leaf and Malt, and then extracted for 40 ~ 120 minutes at 80 ~ 100 ℃. Preparing an extract, licorice extract and malt extract; And
(c) extracting the mushroom mixed extract prepared in the step (a), the Angelica keiskei kots. extract, the mungbean oil extract, the yanggi extract, the bamboo leaf extract, the licorice extract and the malt extract prepared in the step (b) in a ratio of 300: 100: 70: 80: : 10: 10, followed by heating at a temperature of 100 DEG C for 20 minutes.
In the method for producing a mushroom mixed beverage of the present invention, the taste and flavor of the mushroom and herbal extracts can be further improved by mixing the extract in the step (c) and heating under the above conditions, thereby improving the preference degree.
The present invention also provides a mushroom mixed drink produced by the above method. The mushroom mixed drink of the present invention has a reduced odor and bitter taste peculiar to mushroom and herbal medicine, and can be consumed without irritation because of the fragrance of herbs that are felt to be gentle aftertaste, It has functionalities such as protection of liver function and inflammation inhibition effect. By not adding any food additives, it can provide consumers with nutritional supplements, and can provide functional beverages that consumers can take for long-term with peace of mind .
Hereinafter, the present invention will be described in detail with reference to examples. However, the following examples are illustrative of the present invention, and the present invention is not limited to the following examples.
1) Experimental material
The condition and elevation were purchased from Moon Sangyoung mushroom and used. Donggwi, Sansui, Hwanggi, licorice, bamboo leaf and malt were purchased from Dongbu Herbal Medicine Farming Association. The extracts were prepared by adding purified water of 20 times of the total weight ratio provided by Jangheung - gun Mushroom Industry Research Institute and hot - water extraction.
2) Material extraction
The hot water extraction was carried out by cutting the raw materials and adding 20 times of water and varying the extraction temperature and extraction time. That is, water was added at a constant ratio of the weight of each material dried and cut, and the mixture was extracted with shaking with time, centrifuged (4,000 rpm, 15 minutes), and the supernatant was used as each extract (FIGS.
3) Component analysis
A) Free sugar analysis
The free sugar component was prepared by adding distilled water to 5 mL of the sample, grinding it with a homogenizer, stirring, diluting it to 100 mL, centrifuging it at 3,000 rpm for 30 minutes, purifying it with Sep-pak C 18 , The filtrate was filtered using a filter (Millipore Co., USA) and analyzed by HPLC. The analysis conditions are shown in Table 1 and the content is calculated by the external standard method.
(4.6 x 150 mm)
B) Analysis of constituent amino acids
The filtrate obtained by hydrolysis at 110 ° C. for 24 hours was added to 15 mL of 6N HCl solution, and the supernatant was concentrated at 50 ° C. to completely evaporate hydrochloric acid and water. Then, sodium citrate buffer The solution was filtered through a 0.45 ㎛ membrane filter, and analyzed by HPLC using AccQ · Tag method. The HPLC conditions for amino acid analysis are shown in Table 2.
(3.9 x 150 mm)
C) free amino acid analysis
Free amino acid analysis was carried out by adding 25 mg of sulfosalicylic acid to 10 mL of the filtrate obtained by the same method as that of free sugars and allowed to stand at 4 ° C for 4 hours, followed by centrifugation (50000 rpm, 30 minutes) , The supernatant was filtered with a 0.45 ㎛ membrane filter, and the filtrate was used as an analytical sample. Analysis conditions were analyzed under the same conditions as the constituent amino acids.
D)? -Glucan analysis
The? -glucan analysis was performed to determine total glucan and subtract the? -glucan amount to quantify? -glucan. First, 0.1 g of the sample was put into a tube, and 1.5 mL of 37% HCl was added thereto, and the solution was decomposed for 45 minutes in a constant temperature water bath at 30 ° C. Then, 10 mL of distilled water was added to the vortex, followed by incubation at 100 ° C for 2 hours. Then, 10 mL of 2N KOH was added while cooling at room temperature, and the volume was adjusted to 100 mL with 200 mM sodium acetate buffer, followed by thorough mixing. Thereafter, 0.1 mL of exo-1,3- [beta] -glucanase plus [beta] -glucosidase dissolved in 200 mM sodium acetate buffer was added to 0.1 mL of the supernatant, 0.2 mL of acetate buffer was added to the reagent blank, 0.1 mL of D-glucose standard substance and 0.1 mL of acetate buffer were added to D-glucose standards, and the mixture was incubated at 40 ° C for 60 minutes. 3 mL of GOPOD (glucose oxidase / peroxidase mixture) was added and cultured at 40 ° C for 20 minutes. Then, absorbance was measured at 510 nm.
For α-glucan, 0.1 mL of the sample was placed in a tube, 2 mL of 2M KOH was added, and the mixture was mixed for 20 minutes. After adding 8 mL of 1.2 M sodium acetate buffer, add 0.2 mL of amyloglucosidase plus invertase, mix well, and incubate for 30 minutes in a constant-temperature water bath at 40 ° C. To 0.1 mL of the supernatant, 0.1 mL of 200 mM sodium acetate buffer and 3 mL of GOPOD were added and incubated at 40 ° C for 20 minutes and then measured at an absorbance at 510 nm.
4) Manufacture of prototype
The mixing ratios of the sample extracts used in the prototype manufacturing are shown in Tables 3 and 4 below, and the beverage manufacturing process is shown in FIG. Mixing ratio of mushrooms was higher when mixed with 70: 130, 80: 120 and 90: 110 volume ratios (Table 3).
Mixing ratios of extracts for the production of mushroom beverage prototypes are shown in Table 4 below. Mixtures of the condition and the altitude were mixed with 70: 130 volume ratio of the extracts in the condition and elevation.
5) Prototype sensory test
The color, flavor, taste, and overall preference of the 20 panelists were analyzed by 7 - point scale method to determine the mixing ratio of raw materials for the production of highly preferred prototypes. The scoring criteria are very good; 7 points, good; 6 points, good; 5 points, average; 4 points, a little bad; 3 points, bad; 2 points, very bad; 1 point. The number of samples was changed every 2 hours and the same panel was repeated 3 times. The average score was obtained except for the highest score and the lowest score at each iteration. Statistical significance was analyzed by Duncan's multiple comparison method using the SPSS program.
6) Physiological activity of raw materials and prototype
A) Sample preparation method
5 g was added to 100 mL of purified water, and the mixture was extracted at 80 ° C for 3 hours. Then, the mixture was filtered with Whatman filter paper No. 2, The frozen and dried samples were used. Mushroom beverages were used by freeze drying.
B) DPPH free radical scavenging ability
Each sample was diluted with methanol to 0, 10, 50, 250, and 500 ㎍ / mL, and 10 μl of each was added to a 96-well plate. DPPH (2,2-diphenyl-1-picrylhydrazyl) ≪ / RTI > 100 μl of methanol was added to the blank, reacted at room temperature for 30 minutes, and the absorbance at 518 nm was measured to determine DPPH free radical scavenging activity. The DPPH free radical scavenging ability was expressed by the following equation.
DPPH radical scavenging ability (%) = (1 - absorbance of sample addition group / absorbance of sample non-addition group) x 100
C) Hepatocyte protection and function improvement experiment
(1) Collagenase perfusion
Hepatocytes from SD (Sprague-Dawley) rats were isolated by a two-step collagenase perfusion method. To obtain primary rat hepatocytes, SD rats were anesthetized with ether and sterilized with 70% ethanol. The abdomen was opened and the right atrium was opened to allow blood to be removed. The left ventricle was filled with 21 gauge gauge syringe was perfused with 100 mL of HBSS. After removal of the blood, 100 mL of HBSS containing 100 U / mL collagenase was recirculated to allow the hepatocytes to liberate. The liver tissue was removed and 60 mL of HBSS was added in a 100 mm culture dish. 11 chopped with a blade to obtain single cells. To this collagenase suspension, the cells were washed three times with Waymouth's MB 752/1 medium (5% fetal bovine serum, 2.0 mg / mL bovine serum albumin, 10 -6 M dexamethasone, 10 -7 M Insulin, 5.32 × 10 -2 M L-serine, 4.09 × 10 -2 M L-alanine, 2.67 × 10 -2 M NaHCO 3 , 100 IU / mL penicillin, 100 IU / mL streptomycin, 50 μg / mL gentamycin ≪ / RTI > sulfate). Primary rat hepatocytes were diluted to 1 × 10 5 cells / mL and attached to a 96-well plate previously coated with collagen for 4 hours, and then treated with each sample.
(2) liver function test
For liver function tests, Rat primary hepatocytes were cultured in 96-well plates at a concentration of 1 × 10 5 cells / mL. After 24 hours of treatment, 50 μl of the medium was quantitatively analyzed using an LDH (Rat lactate dehydrogenase), an AST (Rat aspartate transaminase) and an ALT (Rat alanine transaminase) ELISA kit purchased from BlueGene Co. . Absorbance was measured at 450 nm using a multiplate reader (BioTek, USA). The concentrations of LDH, AST and ALT in each sample were determined by standard curves at concentrations of 0, 10, 25, 50, 100 and 250 ng / mL.
(3) Inflammation inhibition experiment induced by LPS
(A) Culture of macrophages
Raw 264.7 cells were cultured in DMEM medium supplemented with 10% FBS and 1% antibiotic at 37 ° C in a 5% CO 2 incubator. Cells were subcultured when grown to 80-90% in culture dish and cell passage number was tested only in cells not exceeding 20 cells.
(B) Measurement of nitric oxide (NO) production
The amount of nitric oxide (NO), which is an active nitrogen species generated from RAW 264.7 cells, was measured by reacting NO 2 - form present in the cell culture with a grease reagent. RAW 264.7 cells were seeded in 96-well plates at a concentration of 1 × 10 5 cells / mL, and the samples were treated at different concentrations and cultured for 24 hours. 50 μl of each of the cell culture supernatant (100 μl) and a grease reagent (A reagent: 1% sulfanilamide and B reagent: 25% naphthylethylenediamine 0.1% in phosphate) were mixed and reacted on a 96-well plate for 10 minutes. Absorbance was measured at 540 nm using a plate reader. The NO 2 - standard curve was prepared by concentration of NaNO 2 .
7) Analysis of prototype components
The pH of the prototype was measured with pH meter, the sugar content was measured with sugar solution, and the total acid was titrated with 0.1N NaOH solution, and then 0.009 was multiplied by lactic acid. The lightness, lightness, redness, and yellowness of the lightness, lightness, and yellowness were measured three times with a colorimeter (COLOR JS555, USA). Brightness, redness, and yellowness of the standard white plate were 98.49, -0.02, and -0.40, respectively. Viscosities were measured using a viscometer (BROOKFIELD DV-II + Pro, rtp serial-8484417, spindle 62, brookfield engineering). Free sugars and organic acids were carried out in the same manner as above.
8) Microorganism test of prototype
Bacterial counts were measured by the plate agar culture method after the samples were collected aseptically, and cultured at 37 ° C for 48 hours using a BGLB medium and a Durham fermentation tube. Respectively.
Example 1: Analysis of ingredients of raw materials
1) Free sugar content of raw material
As shown in Table 5, the total free sugar content of raw materials was 37.41%, which was the highest in the order of 16.02%, 13.7%, 12.91%, and 5.2%, respectively. Five kinds of free sugars were detected. The main free sugars were fructose, glucose and sucrose. Trehalose was detected at 1.54% at elevation only.
2) Analysis of constituent amino acids
Table 6 shows the results of measuring the constituent amino acid contents of the raw materials. In total, 16 kinds of amino acids were detected and total amino acid content was 15,221.83 mg%. The total amino acid content of the situation was 9,521.29 mg%, malt 9,731.92 mg%, licorice 7,923.72 mg%, bamboo leaf 11,976.91 mg%, and angelica 10,955.91 mg%. The total amino acid content of corn oil and hwanggi was lower than the other samples.
3) Free amino acid analysis of raw materials
The free amino acid content of the raw materials was measured as shown in Table 7, and a total of 16 kinds of amino acids were detected on the surface, and the total free amino acid content was 4,012.68 mg%. The total free amino acid content of the situation was 1,894.35 mg%, malt 1,850.19 mg%, licorice 1,855.67 mg%, bamboo leaves 2,276.99 mg% and angelica 2,627.31 mg%. Compared with the constituent amino acid contents, all of the sample contents were lowered. In essential oils, three essential amino acids (valine, isoleucine, leucine) and two non - essential amino acids (tyrosine, phenyl alanine) were not detected.
4) Raw material β - glucan analysis
The content of β-glucan in the raw materials was as shown in Table 8, and an elevation of 37.15%, a condition of 19.64%, and malt of 4.62% were detected, but the remaining samples were not detected.
Example 2: Sensory evaluation of mushroom mixed drink
The sensory evaluation showed that the R test was the best in flavor and taste, and the color was excellent in Q test. Compared to the other test groups, the R test group showed the most significant difference in overall acceptability (Table 9). As a result of sensory evaluation, the preference of mushroom beverage had the greatest effect on the addition of the extracts and the addition of the extract of the mushroom extract. As a result, the R test group with the highest sensory test results was selected as the final blend ratio.
Example 3: Analysis of the components of the prototype
Table 10 shows the analysis results of the R test strip, which is a prototype of mushroom drink. The prototype had a pH of 5.32 and a chromaticity of 70.93, a (redness) value of 2.34 and b (yellowness) value of 41.24. The prototype was transparent and yellowish. The sugar content was found to be 5.4 brix. The viscosity was measured at 25 rpm at 20 rpm and the CP value was 2.9.
(brix)
(%)
Example 4: Physiological activity of prototype
1) DPPH free radical scavenging ability
The free radical scavenging activity of DPPH radical scavenging activity of vitamin C, the situation, the BHT, and the concentration of the alcoholic beverages (0, 10, 50, 250, 500 ㎍ / mL) The elimination ability was measured in the order of corn oil, mugwort, angelica, licorice, mushroom drink, malt, mulberry, and hwanggi (Fig. 11). All of the extracts were lower than the vitamin C, which is a positive control, but the extracts were higher than the edible antioxidant BHT. And mushroom beverage showed low DPPH radical scavenging ability, but it showed about 18% scavenging ability at 500 ㎍ / mL concentration.
2) hepatic function-protecting efficacy against acetaminophen
The high concentration of acetaminophen caused toxicity in hepatocytes. As a result of confirming the content of LDH (A in FIG. 12), the content of AST (FIG. 12B) and the content of ALT (FIG. 12C) Extracts, extracts of mushroom, mushroom beverages, extracts of hwanggi, bamboo shoots, and licorice extract.
3) Measurement of NO (Nitric oxide) production
Raw 264.7 macrophages were treated with 1 ㎍ / mL LPS to induce an inflammatory response. Each sample was treated with 100 ㎍ / mL (Fig. 13) And the decrease of inflammatory reaction in the order of extracts.
4) Mushroom beverage microorganism inspection
Table 11 shows the results of the general bacterial test and E. coli test according to the treatment temperature and time after mixing the extracts. General bacteria and Escherichia coli did not occur, and it was found to be microbiologically stable during storage. Therefore, ingestion of this beverage can be proved to be microbiologically safe.
Germ
Claims (5)
(b) After adding water 20 times (w / v) to each of Angelica gigas Nakai, Sansui oil, Hwanggi, Licorice, Liliaceae and Malt, 40 ~ 60 minutes at 85 ~ 95 ℃, 90 ~ 110 to 130 minutes at 95 to 105 ° C for Hwanggi, 30 to 50 minutes at 95 to 105 ° C for licorice, 50 to 70 minutes at 75 to 85 ° C for bracts, 50 to 70 minutes at 85 to 95 ° C Extracts of Angelica keiskei koidz, Extract of Cornus syrup, Hwanggi extract, Bamboo leaf extract, Licorice extract and malt extract; And
(c) extracting the mushroom mixed extract prepared in the step (a), the Angelica keiskei kots. extract, the mungbean oil extract, the yanggi extract, the bamboo leaf extract, the licorice extract and the malt extract prepared in the step (b) in a ratio of 300: 100: 70: 80: : ≪ / RTI > 10: 10, and then heating the mixture at a temperature of 100 DEG C for 20 minutes.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150091759A KR101781954B1 (en) | 2015-06-29 | 2015-06-29 | Method for producing mushroom mixed beverage using Lentinula edodes, Phellinus linteus and medical herb extract and mushroom mixed beverage produced by the same method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150091759A KR101781954B1 (en) | 2015-06-29 | 2015-06-29 | Method for producing mushroom mixed beverage using Lentinula edodes, Phellinus linteus and medical herb extract and mushroom mixed beverage produced by the same method |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20170001972A KR20170001972A (en) | 2017-01-06 |
KR101781954B1 true KR101781954B1 (en) | 2017-09-26 |
Family
ID=57832249
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020150091759A KR101781954B1 (en) | 2015-06-29 | 2015-06-29 | Method for producing mushroom mixed beverage using Lentinula edodes, Phellinus linteus and medical herb extract and mushroom mixed beverage produced by the same method |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101781954B1 (en) |
-
2015
- 2015-06-29 KR KR1020150091759A patent/KR101781954B1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR20170001972A (en) | 2017-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2003988B1 (en) | Natural plant extract composition for prevention and recovery of hyperlipidemia and stroke, natural tea containing the same as active ingredient and method for preparing the natural tea | |
KR101566320B1 (en) | Cosmetic composition comprising an Impatiens balsamina L, Maca, Rosa multiflora Thunberg, Eryobotrya japonica and Pachyrrhizus erosus Complex-fermented extract | |
KR101914344B1 (en) | A moisturizing and anti-wrinkle cosmetic composition comprising fermented barley, fermented pear juice, fermented soybeans and fermented pomegranate extract and the method preparation of thereof | |
KR101425466B1 (en) | Leaf of Smilax china with Aspergillus species, method for preparing the same and use of the same | |
KR20120116374A (en) | Manufacturing method of functional momordica charantia beverage for lowering blood glucose | |
KR101914345B1 (en) | A moisturizing and anti-wrinkle cosmetic composition comprising fermented soybean, fermented rice, fermented potato, fermented ginseng and fermented adlay extract and preparation method of thereof | |
CN107927506A (en) | A kind of more phenolic beverages of high-efficiency antioxidant | |
KR101253658B1 (en) | Manufacturing method of treated puffing and fermentation red ginseng concentrate | |
KR101663379B1 (en) | MANUFACTURE OF FERMENTED Allium hookeri FROM YEASTS AND NATURAL ENZYME AND PREPARATION OF COMBINED BEVERAGE FOR QUENCHING THIRST | |
KR102298700B1 (en) | Facturing method of functional liquefied healthfoods using Gastroia elata Blume and Polygonum multiflorum Thunberg | |
KR101446528B1 (en) | Vinegar Composition Fermented with Black Garlic and Preparation Method Thereof | |
KR102507651B1 (en) | Fermented Stauntonia hexaphylla for hangover relief, alcoholic liver disease or liver function improvement using fermented enzyme complex solution containing traditional brewery yeast and its manufacturing method | |
KR20110098080A (en) | Method for producing health food containing honeybee pollen fermented solution, propolis, honey and royal jelly | |
KR102114133B1 (en) | Composition for hair loss prevention or hair growth stimulation comprising scutellaria alpina extract | |
KR20170053536A (en) | Beverages for preventing respiratory disease and hyperlipidemia containing Platycodon grandiflorum and its preparing method | |
KR20190138066A (en) | kombucha manufacturing method | |
KR101960571B1 (en) | Method for preparing apricot extract, the apricot extract prepared therefrom, and skin care or cosmetic composition comprising the apricot extract | |
CN106281842A (en) | The preparation method of Isatis indigotica Fort (Indigofera tinctoria L, Baphicanthus cusia (nees) Brem. Polygonum tinctorium Ait) fruit wine | |
KR20160060834A (en) | Compositions for culture media of Kefir grain comprising plant extract and compositions for improving skin conditions comprising fermented products using the same | |
KR101781954B1 (en) | Method for producing mushroom mixed beverage using Lentinula edodes, Phellinus linteus and medical herb extract and mushroom mixed beverage produced by the same method | |
CN105441278B (en) | A kind of method of thorny elaeagnus fruit deep processing | |
KR102100989B1 (en) | Method for producing inner beauty beverage using Chrysanthemum zawadskii and fermeted Rhus verniciflua | |
KR20130077911A (en) | Functional food prepared from bamboo sprout vinegar and process for preparing thereof | |
KR102365198B1 (en) | Facturing method of functional liquefied healthfoods using Gastroia elata Blume, Polygonum multiflorum Thunberg and mountain ginseng | |
TWI815324B (en) | Plant ferment and use threrof for preparing weight loss composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |